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Abstract
Cerebral malaria (CM) is associated with a high rate of transient or persistent neurological sequelae. Nogo-A, a protein that is
highly expressed in the endoplasmic reticulum (ER) of the mammalian central nervous system (CNS), is involved in neuronal
regeneration and synaptic plasticity in the injured CNS. The current study investigates the role of Nogo-A in the course of
experimental CM. C57BL/6J mice were infected with Plasmodium berghei ANKA blood stages. Brain homogenates of mice
with different clinical severity levels of CM, infected animals without CM and control animals were analyzed for Nogo-A up-
regulation by Western blotting and immunohistochemistry. Brain regions with Nogo-A upregulation were evaluated by
transmission electron microscopy. Densitometric analysis of Western blots yielded a statistically significant upregulation of
Nogo-A in mice showing moderate to severe CM. The number of neurons and oligodendrocytes positive for Nogo-A did not
differ significantly between the studied groups. However, mice with severe CM showed a significantly higher number of
cells with intense Nogo-A staining in the brain stem. In this region ultrastructural alterations of the ER were regularly
observed. Nogo-A is upregulated during the early course of experimental CM. In the brain stem of severely affected animals
increased Nogo-A expression and ultrastructural changes of the ER were observed. These data indicate a role of Nogo-A in
neuronal stress response during experimental CM.
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Introduction
A major cause of morbidity and mortality of Plasmodium falciparum
malaria is cerebral malaria (CM). It presents as a diffuse
encephalopathy with alteration of consciousness, ranging from
drowsiness to deep coma and is frequently accompanied by seizures
[1]. The pathophysiological mechanisms of CM are yet not fully
understood. Most researchers agree that the immune response of
thehostis a criticalfactorinthe pathogenesisofCM— inparticular
in the murine model [2,3]. In addition neuronal damage, as
evidenced by chromatolysis in large nerve cells, swelling and
vacuolation of the cytoplasm and loss of Nissl granules and glial
degeneration, have been described [4,5]. Neuronal damage is at
least in part attributable to apoptotic mechanisms [6]. A deeper
understanding of the upstream effectors would be necessary for the
development of effective adjunctive treatment strategies aiming at
the reduction of the high mortality of CM and the amelioration of
neurological sequelae which are still observed in approximately
10% of the survivors [7]. In an even higher percentage of survivors
neurocognitive sequelae are expected [8]. Recently, neurodegener-
ation as well as axonal damage have been identified as potential
contributors and were shown to occur in the murine model as well
as in human CM [9–11].
One CNS myelin protein which has gained publicity with
respect to neuronal regeneration is Nogo-A. Nogo belongs to the
reticulon family of proteins which are highly expressed in the
endoplasmic reticulum (ER). Nogo-A is the largest splice variant of
the Nogo gene, which gives rise to three major protein products,
Nogo-A, -B, and -C, by both — alternative splicing and alternative
promoter usage [12]. Nogo-A is exclusively expressed in the
mammalian CNS by oligodendrocytes and certain neurons. Nogo-
A was first identified as an antigen recognized by a monoclonal
antibody against myelin extract [13] and later found to inhibit
neurite outgrowth in the injured mammalian CNS by signaling
involved with the extracellular presentation of Nogo-A and the
binding to its receptor.
However, in the adult central nervous system, Nogo and other
reticulons are also expressed within the neuronal endoplasmic
reticulum (ER) [14]. In this regard Nogo-A might be co-regulated
with ER-associated chaperones and heat-shock protein, serving as
neuroprotectant by preconditioning neurons and glia against ER
stress increasing their resistance to apoptotic insults [14–16].
Recent reports have indicated that Nogo-A protein level is up-
regulated in several animal models for CNS injury, i.e. rat
traumatic brain injury, rat hypoxia-ischemia and focal cerebral
ischemia [17–19]. In addition Nogo-A has been shown to play an
important role in experimental allergic autoencephalitis the
mouse model of multiple sclerosis [20]. However to date Nogo-
A expression has not been studied in infectious diseases of the
CNS.
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alterations of Nogo-A expression in different clinical stages of
experimental CM as a model disease for infectious and
inflammatory pathology of the neurovascular compartment.
Results
Thirty-three of forty-three infected animals developed signs of
CM between day 4 and day 9 post infection with levels of
parasitemia between 5% and 15% (CM group). Ten animals
survived this period and were killed at day 11 post infection. Since
these mice did not show marked neurological signs they served as
an additional control group (NCM group). Parasitemia levels in
the early course of the infection were highly similar between the
two groups (data not shown).
Western blot analysis
In order to determine whether Nogo-A expression is upregu-
lated in the course of CM, brain extracts of mice with different
levels of clinical severity were examined (total n=30, CM1 n=4,
CM2 n=9, CM3 n=6, NCM n=6, CNT n=5). Mice with CM
showed significantly higher densitometric measures for Nogo-A
compared to NCM animals (p,0.05) and non-infected control
animals (p,0.001). Infected mice without neurological signs
(NCM) showed only mildly (not significantly) elevated levels of
Nogo-A compared to CNT mice. Subsequent analyses of mice
with different clinical stages of CM yielded a significant increase of
densitometric measures for Nogo-A in moderately to severely
affected animals (CM2, CM3) (Fig.1A–B). In mice with CM,
correlation analysis did not reveal a significant association between
the cumulative SHIRPA score and OD values for Nogo-A (data
not shown).
Immunohistochemistry
Brains were examined rostrocaudally from bregma +2t o-
6 mm. Cells labeled by antibodies against Nogo-A were observed
in all analyzed samples and brain regions of CNT and CM
animals. Nogo-A labeling was observed in cells showing
morphological characteristics of oligodendrocytes (figure 2A) and
neurons (figure 2B). In CNT animals, brain sections showed mild
labeling for Nogo-A (figure 2, figure 3B, D, F). In CM animals
more intense neuronal and oligodendroglial Nogo-A labeling was
observed (figure 3A, C, E), especially in the brainstem. In order to
quantify these differences morphometric analyses applying stere-
ology were performed. The number of Nogo-A positive cells per
mm
2 with mild (figure 3F) or intense labeling respectively
(figure 3E) were counted in defined regions of the brain (bregma
+2, 0, -2, -4, -6 mm). The total amount of parenchymal cells
positive for Nogo-A irrespective of labeling intensity did not differ
significantly between the studied groups (figure 4A). In frontal
parts of the brain higher densities of Nogo-A positive cells than in
the brain stem or in cerebellum were observed (figure 4A). In the
brain stem, animals with CM3 showed a significantly higher
number of neurons and oligodendrocytes with intense Nogo-A
labeling as compared to CNT, NCM, CM1 and CM2 animals.
(figure 4B, figure 3A, C, E).
Ultrastructural Analysis
To verify whether the increased neuronal Nogo-A expression in
rostral and caudal brainstem in animals with CM is also reflected
by morphological changes, representative samples from these
regions were analyzed by transmission electron microscopy. In
animals with CM, clearly recognizable alterations of the
endoplasmic reticulum were regularly observed. In most neurons
ribosomes and/or polyribosomes appeared conspicuously clus-
tered (figure 5A–B). Some neurons even showed dilated ER and
Golgi apparatus (figure 5A, C). Mitochondria frequently showed
dilated cristae (figure 5B). Control specimens from the same brain
regions did not show signs of neuronal or oligodendroglial
degeneration (figure 5D).
Discussion
Nogo-A is upregulated in the brain of mice with CM during the
early phase of the neurological syndrome. While the total amount
of brain cells with Nogo-A immunolabeling did not increase, the
neuronal and oligodendroglial Nogo-A signal was markedly
intensified especially in the brainstem of mice with CM. In this
brain region ultrastructural alterations suggestive for ER stress
were observed, which might indicate that Nogo-A is involved in
the cellular stress response triggered of by CM.
The role of Nogo-A in the inhibition of axonal sprouting in the
injured adult CNS has been studied extensively [21,22]. In vitro,
presentation of Nogo-A on the cell surface and binding to the
neuronal Nogo receptor is required for the inhibitory effect [23].
Nogo-A has been shown to be upregulated in a variety of disease
Figure 1. Representative Western blot (A) for Nogo-A (200 kDa)
and alpha-tubulin (50 kDa) and densitometric analysis of
western blot experiments (B) in mice with different stages of
cerebral malaria (mild, CM1 n=4; moderate, CM2 n=9; severe
CM3 n=6), infected mice without neurological involvement
(NCM n=6) and uninfected control animals (CNT n=5). A
significant increase of densitometric measures for Nogo-A was
observed in animals with CM compared to NCM and non-infected
control animals. Comparing subgroups of animals with different clinical
levels of severity CM2 and CM3 mice showed significantly higher Nogo-
A levels compared to CNT mice. ***, p.0.001; **, p.0.01; *, p,0.05.
doi:10.1371/journal.pone.0025728.g001
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associated with impaired neuronal regeneration and synaptic
plasticity [17–19, 24]. In cerebral malaria focal neurological signs
and symptoms as well as neurocognitive deficits are observed in a
high percentage of survivors [8]. Although neurological sequelae
are reversible in some patients, others suffer from persisting
disabilities. Especially children are most severely affected [25].
Inhibition of Nogo-A has been shown to increase regeneration
after experimental spinal cord injury [26], and to ameliorate
neurocognitive deficits after experimental traumatic injury [27].
In the current study Nogo-A upregulation was observed in the
very early stage of the neurological syndrome. At this stage
clinical alterations in murine CM are mainly confined to altered
consciousness and alertness [28]. One might hypothesize that
these clinical signs are at least in part attributable to disturbed
synaptic plasticity due to Nogo-A upregulation and that
inhibition of Nogo-A activity could lead to a better functional
outcome. However, the data in traumatic brain injury concerning
genetic deletion or pharmacological inhibition of Nogo-A and
neurocognitive recovery are conflicting [29,30]. Therefore also in
CM a major role of Nogo-A as a repressor of axonal sprouting
and plasticity seems unlikely. The increased expression of Nogo-A
could rather relate to intracellular functions common to the
reticulon protein family [31]. Like other members of the reticulon
family, Nogo-A is associated with the ER and, similarly to RTN-
1, it might be involved in protein transfer, packing and trafficking
[32,33]. It has been shown recently that Nogo-A is a novel
regulator of the ER chaperone protein disulfide isomerase (PDI),
and that through PDI, Nogo-A can protect mice against
neurodegeneration that characterizes amyotrophic lateral sclero-
sis [16]. In the current study, the ultrastructure of neurons in the
brainstem of CM animals was altered. Dilation of the ER
indicated ER stress. In addition, mitochondria frequently showed
altered cristae. Similar morphological patterns have been
observed in ALS but also in an animal model of intoxication
(Manganese) as well as after experimental ischemia [34–36].
These features, are therefore, considered as unspecific indicators
for cellular stress in general and ER stress in particular. In
addition, conspicuously clustered ribosomes / polyribosomes
were observed in our CM samples. This could indicate that also
protein transport is impaired during CM [36]. In this respect the
upregulation of Nogo-A might be interpreted as a cellular
counter-action to inflammatory stress which is known to occur in
murine CM [37]. In line with our observations data from
experimental autoimmune encephalitis and human multiple
sclerosis suggest that Nogo-A has an important function in
inflammatory brain processes [20,38]. The exact role of Nogo-A
in brain inflammation however remains to be resolved. In this
respect further studies are required in other model diseases (e.g.
bacterial meningitis).
In addition to inflammatory processes also ischemia as a
consequence of microcirculatory dysfunction has been suggested to
play a role in murine and human CM [39–41]. Hypoxia /
ischemia has been shown to induce Nogo-A expression [18,19].
Whereas in the first days after focal stroke the total number of
Nogo-A positive neurons decreased, the intensity of neuronal
Nogo-A labeling increased. Our results show that Nogo-A
expression in neurons but not the total number of neurons
positive for Nogo-A is increased in the acute phase of CM. These
observations support the hypothesis that at least in the early phase
after insult Nogo-A upregulation might be regarded as unspecific
cellular response to ischemic stress.
Another common feature of murine CM are epileptic seizures.
Nogo-A mRNA levels have been shown to be elevated in the adult
rat hippocampal neurons after kainate-induced seizures [42].
Furthermore, Nogo-A is induced in hippocampal neurons of
patients with temporal lobe epilepsy [43]. Seizure induced
upregulation could explain the observed increase in Nogo-A
expression in late stage CM. This is certainly not the case for the
very early increase of Nogo-A expression during a CM phase in
which seizures are usually not observed.
The presented data suggest regional differences in the intensity
of Nogo-A upregulation during CM. The brainstem showed more
intense labeling than other regions of interest. Recently, we
demonstrated a similar spatial distribution of a marker for
neuronal apoptosis (i.e. caspase-3 activation) [6]. Importantly,
another experimental study investigated the temporal and spatial
expression of the proto-oncogene product c-fos, an indicator of
cellular stress, and identified the brainstem as an area of
particular vulnerability in CM [44]. It has been shown previously
that Nogo-A labeling is particularly strong in brain stem nuclei
[45]. The higher constitutive expression of Nogo-A in brain stem
neurons and the upregulation of Nogo-A in this region under
Figure 2. Representative micrographs of a non infected control
animal. A: Corpus callosum (bregma -2); B: Cerebellum (bregma -6).
Positive immunolabeling for Nogo-A was observed in cells showing
morphological characteristics of oligodendrocytes (figure 2A) and
neurons (figure 2B). Framed areas in the respective inserts delineate
regions of interest presented in the micrographs. Magnifications: A: 20x,
left inlay 100x; B: 20x.
doi:10.1371/journal.pone.0025728.g002
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regulatory function in this vital brain area in general and in
particular during murine CM.
In conclusion, the current study shows that Nogo-A is
upregulated during the early course of experimental CM with
increased expression in the brain stem of severely affected animals
where ultrastructural changes suggestive for ER stress were
observed. These data suggest a role of Nogo-A in ER associated
neuronal stress response and point to a novel function of Nogo-A
in this model disease for severe immune-mediated pathology of the
neurovascular compartment.
Materials and Methods
Ethics statement
Animal studies conformed to the Austrian guidelines for the
care and use of laboratory animals and were approved by the
Austrian Federal Ministry of Science and Research (permit
number GZ 66.011/53-BrGT/2004).
Animals and Treatment
A total of 54 six to eight weeks old C57BL/6J mice (Charles
River, Sulzfeld, Germany) were used for this study during 3
subsequent experimental infections. Forty-three animals were
infected intraperitoneally with 1*10
6 parasitized red blood cells
of a homologue donor, which had been infected with frozen
polyclonal stocks of Plasmodium berghei ANKA. Eleven animals were
used as non infected control animals (CNT). The clinical severity
of the disease was assessed by the SHIRPA-score primary screen
on baseline, day 5 and before death [28]. The primary screen
comprises a battery of 40 simple tests for evaluating neuromus-
cular, spinocerebellar, sensory, neuropsychiatric and autonomic
functions in mice by observational assessment. The values of the
respective tests were summed up and the cumulative SHIRPA-
score was calculated as described previously [28]. Healthy mice
show a value of about 30 while moribund CM animals show values
of about 10.
Parasitemia was monitored daily by thin blood smear from tail
blood. Between day 6 and day 9 post infection 33 of the infected
mice developed signs of CM and were killed at different clinical
stages of CM as measured by the cumulative SHIRPA score
(CM1 .25, CM2 ,=25 and .=15,CM3,15) or for ethical
reasons as soon as their body temperature dropped to 30uC, a
valid marker for imminent death [28]. Mice which did not
develop cerebral malaria (NCM n=10) were killed on day 11
post infection to minimize suffering, as it is well established that
animals which do not develop CM until day 10 will die from
overwhelming parasitemia about 3 weeks after infection. All
Figure 3. Representative micrographs of an animal with severe CM (A, C, E) and a non infected control animal (B, D, F). A, B, E, F:
bregma -6 (cerebellum and brainstem); C, D: bregma -2 (cortex, hippocampus and thalamic nuclei). In CNT animals, brain sections
showed mild labeling for Nogo-A (B, D, F). In CM animals more intense neuronal and oligodendroglial Nogo-A labeling was observed (A, C, E)
especially in the brainstem (E). Magnifications: A–D: 1x, E-F: 20x.
doi:10.1371/journal.pone.0025728.g003
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(Biochemie, Kundl, Austria) intraperitoneally. Deeply anesthe-
tized mice were transcardially perfused with ice-cold phosphate
buffered saline (PBS) for two minutes followed by ice-cold fixative
solution for 15 min with a pressure controlled syringe pump
(Fresenius-Kabi, Germany).
Western blot
Animals (total n=30, CM1 n=4, CM2 n=9, CM3 n=6,
NCM n=6, CNT n=5) were perfused with PBS for 2 min. Brain
samples were processed as described previously [6]. The
microdissected tissue was homogenized in ice-cold buffer
(pH 7.5) containing 50mM Tris-Cl, 5mM EDTA, 50mM NaCl,
5mM DTT, 0.1% Np-40, 50mM NaF, 1mM PMSF, 1mM
Na3VO4 plus a protease inhibitor cocktail (Roche, Mannheim,
Germany) and centrifuged at 18500g for 20 min at 4uC. Protein
balanced samples were analyzed using standard techniques. The
top parts of the blots were probed with a mouse monoclonal
antibody directed against Nogo-A (11C7; 1:2000 in blocking
solution) overnight at 4uC. 11C7 is directed against amino acids
623–640 of rat Nogo-A. It is specific for Nogo-A and reveals a
single band at 190–210 kD in Western blots of human and murine
brain tissue, and does not cross-react with any other member of
the reticulon family [12]. To control and correct for equal loading,
the bottom part of each blot was probed for alpha-tubulin (Sigma,
1:20000 in blocking solution) overnight at 4uC. Antibody binding
was visualized using Enhanced chemoluminescence reagents
(Lumiglo
TM; Cell Signaling).
Immunohistochemistry
After perfusion with 4% paraformaldehyde in PBS (0.1M),
brains (total n=20, CM1 n=4, CM2 n=4, CM3 n=4, NCM
n = 4 ,C N Tn = 4 )w e r ep o s t f i x e di nt h es a m ef i x a t i v ef o r
6 hours and cryoprotected with 30% sucrose in PBS. Frozen
tissues were cut into 20 mma n d4 0mm thick coronal sections
on a freezing cryotome (Leica Microsystems, Nussloch,
Germany). 20 mm thick sections were mounted on SupraFrost-
Plus slides (Microm International, Walldorf, Germany) and air
dried. 40 mm thick sections were kept in assorter buffer and
stored at 4uC. The directly mounted slides were stained with
Hematoxylin-Eosin according to a standard protocol and used
for the qualitative analysis of the neuropathology of CM. 40 mm
free-floating sections (40 mm) were blocked for endogenous
peroxidase activity (20% methanol containing 1% H2O2) for
20 min and non-specific binding in blocking solution (10%
normal goat serum, 10% bovine serum albumin in Tris-
buffered saline containing 0.1% Triton X-100) for 1 hour at
room temperature. Rabbit polyclonal antibody directed against
Nogo-A (Zymed, CA, USA) was diluted 1:1000 in blocking
solution and permitted to bind overnight at 4uC. Biotinylated
goat anti-rabbit antibody (Vector Laboratories, Burlingame,
CA, USA) was then applied at a dilution of 1:1000 for 1 h at
room temperature. Antibody binding was visualized using
Vectastain ABC kit (Vector Laboratories) and diaminobenzi-
dine as chromogen according to the manufacturer brochure.
Sections without primary antibodies were equally processed to
control for unspecific binding.
Ultrastructural analysis
After perfusion with 3% glutaraldehyde in cacodylate buffer
(0.1M), brains for ultrastructural analysis (total n=4) , were
postfixed in 1% unbuffered aqueous osmium tetroxide for 2 hours
at 4uC and dehydrated in graded ethanol series followed by
infiltration with graded series of Epon epoxy resin. Semi-thin
sections stained with toluidine blue were screened for areas of
interest. Subsequently, 100 nm sections were cut on an ultrami-
crotome, contrasted with uranyl acetate and lead citrate and
viewed with a CM120 transmission electron microscope (Philips,
Eindhoven, The Netherlands).
Morphometric analysis
For morphometric analysis anatomical regions of interest
(ROI) between +2a n d– 6b r e g m a( 6350 mm) were determined
as previously described [28]. Stereology was applied using a
computer-assisted image analysis system: Nikon E-800 micro-
scope with a motorized stage and Stereo Investigator Software
(MicroBrightField, Magdeburg, Germany). The optical frac-
tionator stereological method was used to count parenchymal
cells positive for Nogo-A [46]. One section per ROI from each
animal was examined in a blinded way with objective6100 with
ac o u n t i n gf r a m eo f7 0 650 mma n das a m p l i n gg r i da r e ao f
70061000 mm. Only extravascular cells with a clear labeling
and morphological characteristics of neurons or glia were
counted.
Figure 4. Stereological analysis of the number of Nogo-A
positive cells per mm
2 (A) and the ratio of Nogo-A positive
cells per mm
2 with intense labeling in relation to mildly
labeled cells (B) in defined regions of the brain (bregma +2, 0,
-2, -4, -6 mm). The total amount of parenchymal cells positive for
Nogo-A did not differ significantly between the studied groups (A). In
the brain stem animals with severe CM showed a significantly higher
number of neurons and oligodendrocytes with intense Nogo-A labeling
(B). **, p,0.001 for the comparison CM3 vs. CM2, CM1, CNT and p,0.01
for the comparison CM3 vs. NCM; *, p,0.01 for the comparison CM3 vs.
NCM and p,0.05 for the comparison CM3 vs. CM1, CNT. Mean and SEM
are shown.
doi:10.1371/journal.pone.0025728.g004
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Spearman rank correlation was calculated between OD values
for Nogo-A and the cumulative SHIRPA score. OD values of
Nogo-A were compared between groups by Kruskal-Wallis test
and Dunn’s multiple comparison test. Nogo-A positive brain
parenchymal cells were compared between groups by two-way
ANOVA with anatomical ROI and clinical severity group as
factors. P-values were Bonferroni-corrected for multiple compar-
isons. All statistical analyses were done using GraphPad Prism
version 5.00 (GraphPad Software, San Diego California USA).
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Figure 5. Transmission electron microscopic micrographs of animals with CM (A-C) and an uninfected control animal (D). In animals
with CM, ultrastructural changes indicating alterations of the endoplasmic reticulum (ER) were observed. In most neurons ribosomes and / or
polyribosomes appeared conspicuously clustered (A-B, arrows). Some neurons even showed dilated ER (C, arrow-heads) and Golgi apparatus
(A,C: g). Mitochondria (m) frequently showed altered cristae (B: asterisks). Control specimens from the same brain regions did not show signs
of neuronal or oligodendroglial degeneration (D). Golgi apparatus are marked by g; mitochondria by m, nuclei by n. Bars in A, B, C, D
correspond to 1 mm. Framed areas in A, B, D are shown at higher magnification in the respective inserts, where the bars correspond to
0.5 mm.
doi:10.1371/journal.pone.0025728.g005
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